FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890360611> ?p ?o ?g. }

• W2890360611 endingPage "193" @default.
• W2890360611 startingPage "183" @default.
• W2890360611 abstract "To evaluate the long-term efficacy and prognostic factors of ultrasound-guided percutaneous radiofrequency ablation (RFA) for breast cancer liver metastasis (BCLM).Between 2000 and 2015, 69 patients who underwent ultrasound-guided percutaneous RFA for BCLM and had regular follow-up examinations were included. All patients had undergone resection of the primary breast cancer and had received chemotherapy, endocrine therapy or both after surgery. The sample included two males and 67 females with an average age of 50.3 ± 10.0 years (31-76 y). The mean maximum diameter of metastatic lesions in the liver was 2.9 ± 1.4 cm (1.0-6 cm). Thirty-five patients had a single metastasis, while 34 patients had multiple liver metastases (2-5 lesions). Survival results were generated using Kaplan-Meier estimates and a multivariate analysis was performed using the Cox regression model.In total, 92 RFA sessions were performed and 135 BCLM lesions were treated. Major complications occurred in one of the 92 sessions (1.1%). Technical efficacy was achieved in 92.6% of lesions (125/135 lesions). Local tumor progression occurred in 11.6% (8/69) of patients and new intrahepatic metastasis occurred in 55.1% (38/69) of patients. From the time of initial RFA, the median overall survival was 26 months, and the one-, two-, three- and five -year survival rates were 81.8, 50.1, 25.3 and 11.0%, respectively. Based on the multivariate analysis, the following three factors were identified as independent prognostic factors for overall survival: tumor size (p = .017), positive estrogen receptor status (p = .009) and extrahepatic metastatic disease (p = .001). The median progression-free survival was 24 months, and the one-, two-, three- and five -year survival rates after RFA were 77.4, 47.0, 23.7 and 8.5%, respectively. Additionally, the independent prognostic factors for progression-free survival included tumor size (p = .011), ER positivity (p = .001), margin size (p = .017) and extrahepatic metastatic disease (p < .001).The results of this study showed that RFA is a safe and locally effective method for the treatment of BCLM, especially in patients with lesions measuring less than 3 cm in diameter, a single liver metastasis, positive estrogen receptor status and no extrahepatic metastases. Also, patients with margin size >10 mm had no local tumor progression." @default.
• W2890360611 created "2018-09-27" @default.
• W2890360611 creator A5011813195 @default.
• W2890360611 creator A5029009109 @default.
• W2890360611 creator A5036399590 @default.
• W2890360611 creator A5037796144 @default.
• W2890360611 creator A5039980122 @default.
• W2890360611 creator A5060522654 @default.
• W2890360611 creator A5066264669 @default.
• W2890360611 creator A5083820426 @default.
• W2890360611 date "2018-09-10" @default.
• W2890360611 modified "2023-10-14" @default.
• W2890360611 title "Long-term outcomes and prognostic analysis of percutaneous radiofrequency ablation in liver metastasis from breast cancer" @default.
• W2890360611 cites W1854253459 @default.
• W2890360611 cites W1949143911 @default.
• W2890360611 cites W1966142599 @default.
• W2890360611 cites W1969793744 @default.
• W2890360611 cites W1973696837 @default.
• W2890360611 cites W1975537551 @default.
• W2890360611 cites W1980125421 @default.
• W2890360611 cites W1984988266 @default.
• W2890360611 cites W1995053561 @default.
• W2890360611 cites W2000180049 @default.
• W2890360611 cites W2005617864 @default.
• W2890360611 cites W2018650606 @default.
• W2890360611 cites W2018932043 @default.
• W2890360611 cites W2021994072 @default.
• W2890360611 cites W2023755204 @default.
• W2890360611 cites W2031213807 @default.
• W2890360611 cites W2046546462 @default.
• W2890360611 cites W2047259303 @default.
• W2890360611 cites W2053863626 @default.
• W2890360611 cites W2061381781 @default.
• W2890360611 cites W2062889854 @default.
• W2890360611 cites W2066390717 @default.
• W2890360611 cites W2091287424 @default.
• W2890360611 cites W2096759906 @default.
• W2890360611 cites W2102397760 @default.
• W2890360611 cites W2104811890 @default.
• W2890360611 cites W2110069371 @default.
• W2890360611 cites W2115547760 @default.
• W2890360611 cites W2129051037 @default.
• W2890360611 cites W2134068014 @default.
• W2890360611 cites W2138679901 @default.
• W2890360611 cites W2143757865 @default.
• W2890360611 cites W2169334668 @default.
• W2890360611 cites W2302812798 @default.
• W2890360611 cites W2330950012 @default.
• W2890360611 cites W2513655888 @default.
• W2890360611 cites W2562903699 @default.
• W2890360611 cites W2595288363 @default.
• W2890360611 cites W2609928112 @default.
• W2890360611 cites W2615677011 @default.
• W2890360611 cites W2623364824 @default.
• W2890360611 cites W2773761944 @default.
• W2890360611 cites W2917837889 @default.
• W2890360611 doi "https://doi.org/10.1080/02656736.2018.1488279" @default.
• W2890360611 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30200791" @default.
• W2890360611 hasPublicationYear "2018" @default.
• W2890360611 type Work @default.
• W2890360611 sameAs 2890360611 @default.
• W2890360611 citedByCount "25" @default.
• W2890360611 countsByYear W28903606112019 @default.
• W2890360611 countsByYear W28903606112020 @default.
• W2890360611 countsByYear W28903606112021 @default.
• W2890360611 countsByYear W28903606112022 @default.
• W2890360611 countsByYear W28903606112023 @default.
• W2890360611 crossrefType "journal-article" @default.
• W2890360611 hasAuthorship W2890360611A5011813195 @default.
• W2890360611 hasAuthorship W2890360611A5029009109 @default.
• W2890360611 hasAuthorship W2890360611A5036399590 @default.
• W2890360611 hasAuthorship W2890360611A5037796144 @default.
• W2890360611 hasAuthorship W2890360611A5039980122 @default.
• W2890360611 hasAuthorship W2890360611A5060522654 @default.
• W2890360611 hasAuthorship W2890360611A5066264669 @default.
• W2890360611 hasAuthorship W2890360611A5083820426 @default.
• W2890360611 hasBestOaLocation W28903606111 @default.
• W2890360611 hasConcept C121608353 @default.
• W2890360611 hasConcept C126322002 @default.
• W2890360611 hasConcept C126838900 @default.
• W2890360611 hasConcept C141071460 @default.
• W2890360611 hasConcept C2776283816 @default.
• W2890360611 hasConcept C2777377203 @default.
• W2890360611 hasConcept C2778902805 @default.
• W2890360611 hasConcept C2779013556 @default.
• W2890360611 hasConcept C2780813298 @default.
• W2890360611 hasConcept C50382708 @default.
• W2890360611 hasConcept C530470458 @default.
• W2890360611 hasConcept C71924100 @default.
• W2890360611 hasConceptScore W2890360611C121608353 @default.
• W2890360611 hasConceptScore W2890360611C126322002 @default.
• W2890360611 hasConceptScore W2890360611C126838900 @default.
• W2890360611 hasConceptScore W2890360611C141071460 @default.
• W2890360611 hasConceptScore W2890360611C2776283816 @default.
• W2890360611 hasConceptScore W2890360611C2777377203 @default.
• W2890360611 hasConceptScore W2890360611C2778902805 @default.
• W2890360611 hasConceptScore W2890360611C2779013556 @default.
• W2890360611 hasConceptScore W2890360611C2780813298 @default.

• next